drugset / Trial / NCT01345864
Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults
RandomizedParallel-groupDouble-blindBasic science
Summary
This study is designed to look at the potential for an investigational drug (PF-04995274, under development by Pfizer, Inc. as a potential treatment for Alzheimer's disease) to reverse changes in memory and learning/problem solving skills caused by co-administration of a marketed drug called scopolamine. Scopolamine is known to cause temporary changes in memory and learning/problem solving skills that are similar to those seen in people with alzheimer's disease(AD).
Timeline
- Start
- 2011-05
- Primary completion
- 2011-07
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donepezil | Small molecule | 5 mg | Oral |
| Subject | Donepezil | Small molecule | 10 mg | Oral |
| Subject | PF-04995274 | Small molecule | 0.25 mg | Oral |
| Subject | PF-04995274 | Small molecule | 15 mg | Oral |
| Background | Scopolamine | Unknown | 0.5 mg | Subcutaneous |
Indications
No indication recorded.